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Abstract 
Background: Combination of dexmedetomidine and opioid may be an alternative to high-dose opioid in 
attenuating cough during emergence from anesthesia, while also reducing the adverse effects of high-dose 
opioid. We tested the hypothesis that a single-dose of dexmedetomidine combined with low-dose 
remifentanil infusion during emergence would not be inferior to high-dose remifentanil infusion alone in 
attenuating cough after thyroidectomy. 
Methods: One hundred sixty-nine patients undergoing thyroidectomy were enrolled and randomized in 
a 1:1 ratio into group DR or group R. Each patient received an infusion of dexmedetomidine (0.5 μg/kg) 
and low-dose remifentanil infusion of effect-site concentration (Ce) at 1 ng/mL or normal saline and 
high-dose remifentanil infusion of Ce at 2 ng/mL for 10 min at the end of surgery. Remifentanil was 
maintained until tracheal extubation. Primary endpoint was the severity of coughing, which was assessed 
for non-inferiority using a four-point scale at the time of extubation. For comparison of coughing 
incidence during emergence, coughing grade was also measured at three times: before extubation, at 
extubation, and after extubation. Time to awakening, hemodynamic and respiratory profile, pain, and 
postoperative nausea and vomiting were also evaluated for superiority.  
Results: The 95% confidence intervals for differences in cough grade during tracheal extubation were 
<0.9, indicating non-inferiority of the single dose of dexmedetomidine combined with low-dose 
remifentanil infusion. The incidence of coughing was similar in the two groups. Hemodynamic changes 
during tracheal extubation were attenuated, but emergence from anesthesia was delayed, in group DR. 
Use of rescue antiemetic was similar in both groups, but the incidence of vomiting was less in group DR. 
Conclusion: A single-dose of dexmedetomidine (0.5 μg/kg) combined with low-dose remifentanil 
infusion at 1 ng/mL of Ce during emergence from sevoflurane-remifentanil anesthesia was not inferior to 
high-dose remifentanil infusion alone at 2 ng/mL of Ce with regard to suppressing cough. 
 
Introduction 
Coughing during emergence from general 
anesthesia is a critical issue in patient care in the 
perioperative period [1] as it may lead to surgical 
bleeding, laryngospasm, and cardiovascular 
instability. Maintenance of remifentanil infusion, 
which is conventionally used as an adjuvant in 
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general anesthesia, attenuates coughing during 
emergence in dose-related manner [2]. However, 
further increasing the dose of remifentanil may cause 
respiratory depression, delayed emergence, and 
aggravate postoperative nausea and vomiting.  
Dexmedetomidine is a highly selective 
α2-adrenoreceptor agonist that has sedative, analgesic, 
and sympatholytic properties, without respiratory 
depression [3, 4]. A previous study showed that 
addition of a single dose of dexmedetomidine (0.5 
μg/kg) during emergence was more effective in 
preventing cough than remifentanil infusion alone [5]. 
However, the remifentanil dose in this study was an 
insufficient amount to suppress coughing during 
emergence, compared to previous studies. Therefore, 
it remains unknown whether the addition of single- 
dose dexmedetomidine to low-dose remifentanil 
infusion is as effective as high-dose remifentanil 
infusion alone for suppressing emergence cough and 
whether it may also reduce the adverse events related 
to high-dose opioids. 
Therefore, we hypothesized that a single dose of 
dexmedetomidine (0.5 μg/kg) combined with 
low-dose remifentanil infusion during emergence 
from general anesthesia would not be inferior to 
high-dose remifentanil infusion alone in attenuating 
cough, in addition to reducing the adverse events 
related to high-dose remifentanil. This prospective, 
two parallel-group randomized, single-center non- 
inferiority trial was aimed at comparing the efficacy of 
a dexmedetomidine bolus with low-dose remifentanil 
infusion and high-dose remifentanil infusion alone in 
attenuating coughing during emergence from 
sevoflurane-remifentanil anesthesia after thyroidecto-
my. The primary outcome was the severity of 
coughing at extubation. Secondary outcomes were the 
incidence of coughing during emergence from general 
anesthesia, which was measured three times, and 
recovery profiles. 
Materials and Methods 
Patients 
This randomized controlled trial was approved 
by the Institutional Review Board of Gangnam Sever-
ance Hospital, Yonsei University College of Medicine, 
Seoul, Korea; protocol number: 3-2013-0192. This trial 
was registered at clinicaltrials.gov (NCT02208505); 
date of registration: February 2014. American Society 
of Anesthesiologists (ASA) class I-II adults 
undergoing elective thyroidectomy were enrolled in 
our study after providing written informed consent. 
Exclusion criteria included presence of an upper 
respiratory infection or asthma, potential problem 
with airway management, hepatic dysfunction, 
uncontrolled hypertension (systolic blood pressure 
>160 mmHg or diastolic blood pressure >90 mmHg) 
or active coronary artery disease.  
Randomization  
Patients were randomly assigned to two groups 
in a 1:1 ratio by a computer-based randomization 
program (http://www.random.org/). The randomi-
zation result was kept sealed in an envelope, and only 
an anesthesiologist blinded to the patient assessment 
was allowed to open the envelope and prepare the 
assigned drug. Each patient received an infusion of 
dexmedetomidine (0.5 μg/kg) and low-dose remifent-
anil infusion at 1 ng/mL of effect-site concentration 
(Ce) in group DR or normal saline and high-dose 
remifentanil infusion at 2 ng/mL of Ce in group R for 
10 min at the end of surgery. 
Anesthetic management 
Premedication comprised intravenous glycopyr-
rolate (0.1 mg) and midazolam (1–2 mg). Upon arrival 
in the operating room, standard monitors (pulse 
oximetry, electrocardiogram, and non-invasive blood 
pressure) were applied to the patients. Anesthesia 
was induced with propofol (1.5 mg/kg) and 
remifentanil (1 ng/mL) of Ce. The Ce of remifentanil 
using Minto’s pharmacokinetic model was maintain-
ed with a commercial target-controlled infusion (TCI) 
system (Orchestra Base Primea; Fresenius Vial, 
Brezins, France). After adequate muscular relaxation 
with administration of intravenous rocuronium (0.6 
mg/kg), an tracheal tube with an internal diameter of 
6.5 mm (female) or 7.5 mm (male) was sited. Cuff 
pressure of the endotracheal tube was maintained at 
20–25 cmH2O. The patient’s lung was ventilated with 
a tidal volume of 8 mL/kg of ideal body weight. 
Ventilation frequency was adjusted to maintain 
4.6–5.3 kPa of end-tidal CO2 (ETCO2) partial pressure 
in 50% O2/air. During surgery, sevoflurane was 
adjusted to 2%–2.5% and remifentanil TCI was 
adjusted to 1.5–4.0 ng/mL to maintain heart rate and 
blood pressure within 20% of preoperative baseline 
values. 
When the surgeon began placing subcutaneous 
sutures, inhaled sevoflurane was titrated to 1% and 
the Ce of remifentanil was titrated to 1 ng/mL in 
group DR and to 2 ng/mL in group R and maintained 
until extubation in both groups. Dexmedetomidine or 
normal saline was injected slowly for 10 min 
according to the group. Ketorolac (60 mg) and 
ondansetron (4 mg) were administered intravenously. 
After completion of skin suturing, sevoflurane was 
turned off and 100% oxygen flow was adjusted to 6 
L/min until the time of extubation. After confirmation 
of same responses visually to double-burst 
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stimulation, neostigmine and glycopyrrolate were 
administered. Then, the ETCO2 was adjusted between 
4.6–5.9 kPa with manual ventilation. The patient was 
stimulated gently with continuous verbal requests to 
open his or her eyes and light touch of the patient’s 
shoulder at 15-s intervals. When the patient opened 
his or her eyes in response to stimuli and recovered 
full spontaneous respiration, extubation was 
performed. Simultaneous with extubation, remifen-
tanil was discontinued and 100% oxygen was given 
via a face mask for 5 min. All patients were 
transferred to the post-anesthetic care unit (PACU) 
after surgery.  
Study Endpoints and other assessments 
An anesthesiologist who did not participate in 
anesthesia and was blinded to the patient’s treatment 
group assessed the severity and incidence of 
coughing. The severity of coughing was graded on a 
4-point scale: 0, no cough; 1, single cough; 2, more 
than one episode of unsustained cough; 3, sustained 
and repetitive cough with head lift [6]. Also, severe 
cough was defined as cough grade 3. Primary 
endpoint was the severity of coughing at the time of 
extubation. For the evaluation of incidence of 
coughing during emergence from general anesthesia 
as secondary outcomes, coughing was measured at 
three times: before extubation, at extubation, and after 
extubation. 
Another anesthesiologist, who did not assess the 
coughing grade, recorded the time from discontinua-
tion of sevoflurane to first eye opening (time to 
awakening) and extubation. The following parame-
ters were recorded before induction of anesthesia, 
before dexmedetomidine/normal saline infusion, 
immediately after completion of dexmedetomidine/ 
normal saline infusion, and during extubation: 
respiratory rate, mean arterial pressure, heart rate, the 
Ramsay Sedation Scale. The length of a patient’s stay 
in the PACU was recorded as were any adverse 
events, such as hypertension, hypotension, bradycar-
dia (<60 beats/min), oxygen desaturation (<90%), 
breath-holding, laryngospasm, pain, or postoperative 
nausea and vomiting. Adverse events were managed 
according to institutional standards. Pain, postopera-
tive nausea and vomiting, and use of analgesics and 
antiemetics were evaluated 24 h after surgery in the 
ward. 
The quality of recovery after general anesthesia 
was assessed using the quality of recovery 40 item 
(QoR-40) questionnaire, which addresses five 
dimensions of recovery: physical comfort, emotional 
state, physical independence, psychological support, 
and pain. Each item was rated on a 5-point scale: none 
of the time, some of the time, usually, most of the 
time, and all of the time. The total score of the QoR-40 
ranges from 40 (poor recovery) to 200 (good 
recovery). The QoR-40 questionnaire was administ-
ered twice, the day of surgery before the induction of 
general anesthesia and the day after surgery. 
Statistical Analysis 
Statistical analysis was performed by a medical 
statistician who was blinded to group allocation using 
SAS software 9.2 (SAS, Inc., Cary, NC, USA) and 
PASW statistics 23.0 Windows (SPSS, Chicago, IL, 
USA). The primary endpoint was the difference in 
cough grade at tracheal extubation. Non-inferiority 
design was more appropriate than equivalence 
design, since the clinical hypothesis was that 
dexmedetomidine with low-dose remifentanil could 
be as effective for cough suppression as high-dose 
remifentanil alone with lower adverse effect by 
opioid. Null hypothesis of the study was that 
dexmedetomidine with low-dose remifentanil is 
associated with a <10% increase of coughing grade 
during extubation than high-dose remifentanil alone. 
The alternative hypothesis we assessed in our study 
for non-inferiority was that dexmedetomidine with 
low-dose remifentanil is associated with a <10% 
increase of coughing grade during extubation than 
high-dose remifentanil alone. We defined our margin 
for non-inferiority (10%) empirically, as we could not 
find any existing study that combined dexmedeto-
midine with low/high remifentanil to compare cough 
grade. 
A prior study showed that the 95% CI of median 
difference in cough grade was [0.999993, 1.999963] 
between two groups [7]. We assumed the non-inferio-
rity margin to be 0.9, and a sample size of 79 patients 
in each group was estimated to be required to obtain 
80% power with an alpha level of 0.05. The previous 
dropout rate was very low at 1% [5]. We considered 
the dropout rate of this study to be 8%, and 85 
patients per group were recruited and randomized. 
All values are expressed as number of patients 
(percentage), mean ± standard deviation, or median 
value [q1-q3 range]. The assumption of normality was 
checked using Shapiro-Wilk test. Discrete variables 
between the groups were compared using a 
chi-square test or Fisher’s exact test. Repeated 
measurements were analysed using linear mixed 
models with a Bonferroni correction. Data were 
considered to be statistically significant with p-value 
less than 0.05. 
Results 
Enrolled patients (n=170) were randomized into 
the two study groups (Fig 1). In group DR, two 
patients did not receive the allocated intervention, 
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due to a prolonged intubation time for one patient 
and unstable hemodynamics for the other. In group R, 
four patients did not receive the allocated 
intervention, due to prolonged intubation time for 
three patients and intraoperative damage to recurrent 
laryngeal nerve for one patient. Three patients in 
group DR and one patient in group R were excluded 
because of protocol violations. Four patients in each 
group refused to complete the QoR-40 questionnaire 
after surgery. They were excluded from the analysis 
of the quality of recovery after general anesthesia, but 
their characteristics and cough grade, hemodynamic 
stability during tracheal extubation were recorded. 
Demographic and surgical characteristics were 
similar in the two groups (Table 1). 
The 95% confidence intervals for the mean 
differences in cough grade at tracheal extubation were 
<0.9, which was within the margin of non-inferiority 
(Fig 2). The overall incidence of coughing or severe 
coughing (cough grade=3) was similar in the groups. 
In addition, the median values of cough grade during 
extubation were not significantly different in the two 
groups (Table 2).  
Group R showed elevation of mean arterial 
pressure and heart rate at tracheal extubation (Fig 3), 
but group DR did not. During the infusion of dexme-
detomidine, bradycardia (<60 beats/min) was noted 
in 16 patients (20%). Bradycardia resolved spontaneo-
usly after completion of the dexmedetomidine 
infusion, except in two patients who had hypotension 
(mean arterial pressure <60 mmHg) with bradycardia 
and were treated with intravenous ephedrine (4–8 
mg).  
The time to awakening and extubation were 
longer in group DR than in group R (Table 3). The 
trend shows better preservation of spontaneous 
respiration at awakening in group DR, but it didn’t 
reach statistical significance. The length of PACU stay 
was not different in the two groups. Oxygen 
desaturation or respiratory difficulty was not 
observed in either group during PACU stay. 
Hemodynamic differences during extubation between 
two groups resolved spontaneously in PACU.  
 
Table 1. Patient characteristics and intraoperative data 
  Group DR (n=79) Group R (n=80) 
Sex (M/F) 20/59 22/58 
Age (years) 43 ± 11 42 ± 9 
BMI 24.2 ± 3.8 24.3 ± 3.4 
ASA physical status (I/II) 62/17 60/20 
Smoker 6 (7%) 5 (6%) 
Duration of anesthesia (min) 120 ± 36 116 ± 37 
Data are presented as number of patients (%) or mean ± standard deviation as 
appropriate. NA, not applicable; BMI, body mass index; ASA, American Society of 
Anesthesiologists.  
 
Table 2. Incidence and severity of coughing during emergence 
from anesthesia 
  Group DR (n=79) Group R (n=80) p-value 
Incidence of:     
 Any cough 56 (70%) 65 (81%) 0.140 
 Severe cough 12 (15%) 14 (18%) 0.831 
Cough grade:    
 Before extubation 1.00 ± 1.18 0.88 ± 1.09 0.535 
 At extubation 0.68 ± 0.74 1.00 ± 0.83 0.012 
 After extubation 0.10 ± 0.47 0.23 ± 0.69 0.189 
Severe cough = grade 3 (sustained and repetitive coughing with head lift). Values 
are number (percentage) or mean ± standard deviation. 
 
 
Figure 1. Consolidated Standards of Reporting Trials (CONSORT) Diagram. 
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Figure 2. Differences in mean cough grade during tracheal extubation. 
Vertical line at 0.9 represents margin of non-inferiority for the cough grade. The 
horizontal bars represent one-sided 95% confidential intervals. 
 
Figure 3. Hemodynamic changes during anesthesia. T0, baseline; T1, before 
infusion of dexmedetomidine or saline; T2, after infusion of dexmedetomidine or 
saline; T3, at extubation. *p<0.05 compared with placebo group (Bonferroni 
corrected). +p <0.05 compared with baseline in each group (Bonferroni corrected). 
Error bars show standard deviation. 
 
There was no difference in the use of analgesics 
between two groups during the 24 h after surgery 
(Table 3). Rescue antiemetic was used more 
frequently in group R in the 24 h after surgery in the 
ward, although the difference was not significant 
(p=0.086). However, the five patients with vomiting 
belonged to group R (p=0.024). 
The QoR-40 questionnaire was administered 
twice. Thus, linear mixed model was employed to 
examine differences in pre-/postoperative QoR-40 
score between groups (Table 4). There was a 
significant difference between two groups in the 
global QoR-40 score (p=0.049). In each dimensional 
analysis, emotional state and physical independence 
showed difference between two groups.  
Discussion 
In this prospective, randomized study, we 
demonstrated that a single dose of dexmedetomidine 
(0.5 μg/kg) in addition to a remifentanil infusion at 1 
ng/mL of Ce during emergence from sevoflurane- 
remifentanil anesthesia was not inferior to a 
remifentanil infusion alone at 2 ng/mL of Ce with 
regard to attenuating cough. Addition of dexmedeto-
midine bolus to low-dose remifentanil infusion 
suppressed the hemodynamic response to tracheal 
extubation and postoperative nausea and vomiting, 
although it did not improve the respiratory profile, 
compared to high-dose remifentanil infusion. 
 
Table 3. Recovery profile  
 Group DR 
(n=79) 
Group R 
(n=80) 
p-value 
Time to awakening (min) 8 ± 3 7 ± 2 <0.001 
Spontaneous respiration at awakening 34 (43%) 24 (30%) 0.101 
Time to extubation (min) 10 ± 3 8 ± 2 0.012 
Ramsay score at extubation 3 [2-3] 3 [2-3] 0.58 
Spontaneous respiration rate (/min):     
  during tracheal extubation 13 ± 15 11 ± 4 0.315 
 5 min after tracheal extubation 12 ± 4 13 ± 4 0.485 
Length of stay at PACU (min) 50 (40–60) 46.5 (40–60) 0.868 
Additional analgesics in PACU 34 (43%) 45 (56%) 0.385 
Anti-emetics in PACU  3(4%) 5 (6%) 0.491 
Additional analgesics in ward 66 (84%) 70 (87%) 0.839 
Anti-emetics in ward 58 (73%) 67 (84%) 0.086 
Vomiting in ward 0 5 (6%) 0.024 
Hoarseness in ward 0 4 (5%) 0.044 
Time to awakening is the time from discontinuation of sevoflurane to spontaneous 
eye opening or eye opening in response to light stimulation. Time to extubation is 
the time from discontinuation of sevoflurane to extubation. PACU, post-anesthesia 
care unit. Data are expressed as mean ± SD, difference (95% CI) or median [q1-q3 
range]. 
 
Table 4. Quality of recovery questionnaire QoR-40 dimensions 
and global score 
QoR-40 dimensions Group DR (n=75)* Group R (n=74)* p-value 
Emotional state     0.048 
 Preoperative 38.0 ± 7.2 39.5 ± 6.3  
 Postoperative 38.6 ± 5.3 38.4 ± 6.3  
Physical comfort     0.069 
 Preoperative 52.0 ± 9.7 54.1 ± 5.6  
 Postoperative 50.8 ± 6.0 50.3 ± 8.5  
Psychological support     0.143 
 Preoperative 32.3 ± 5.0 33.4 ± 2.8  
 Postoperative 32.5 ± 3.3 32.5 ± 4.0  
Physical independence     0.038 
 Preoperative 19.0 ± 2.7 19.5 ± 1.3  
 Postoperative 22.0 ± 3.7 21.1 ± 4.0  
Pain     0.689 
 Preoperative 32.1 ± 6.2 32.1 ± 3.4  
 Postoperative 27.1 ± 4.5 26.6 ± 5.6  
Global QoR-40 score     0.046 
 Preoperative 173.0 ± 29.8 178.6 ± 16.1  
 Postoperative 171.0 ± 19.0 168.9 ± 23.6  
Values are mean ± SD. *Four patients in group DR and six patients in group R 
refused to complete the QoR-40 questionnaire after surgery. 
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Coughing during emergence from anesthesia 
can result from irritant or stretch stimuli caused by 
the endotracheal tube [8]. Thus various methods to 
prevent coughing during emergence, including 
application of topical local anesthetics [9] and use of 
hypnotics [10, 11] and opioids [1, 12] to deepen 
anesthesia, have been tried. Further, maintenance of 
high-dose remifentanil during emergence was 
reported to be effective in reducing the incidence and 
severity of coughing [1]. In a previous study, 
additional dexmedetomidine was proven to be effect-
ive in reducing the incidence of cough after surgery 
[5]. Although that study demonstrated the efficacy of 
additional dexmedetomidine in preventing coughing, 
to date no study has compared the use of additional 
dexmedetomidine and low-dose remifentanil with 
high-dose remifentanil alone. Thus, the fact that we 
compared the two methods previously demonstrated 
to be effective in lowering cough strengthens our 
findings. Addition of dexmedetomidine to low-dose 
remifentanil is as effective as high-dose remifentanil 
in attenuating the severity and incidence of 
emergence cough after thyroidectomy. This protective 
effect of dexmedetomidine during emergence might 
have been due to deepening of sedation rather than a 
specific antitussive effect, as previously described [5, 
13]. 
The dexmedetomidine dose was based on the 
previous study that concluded that addition of a 
single dose (0.5 μg/kg) of dexmedetomidine 
effectively attenuates coughing during emergence 
from sevoflurane-remifentanil anesthesia, when 
compared to maintenance of low-dose remifentanil 
infusion alone at 1 ng/mL [5]. We chose a 
remifentanil Ce of 2 ng/mL, which is close to the EC95 
of remifentanil in suppressing cough during 
emergence from propofol-remifentanil anesthesia [2], 
although Jun et al reported that remifentanil Ce of 1.5 
ng/mL reduces emergence cough from sevoflurane- 
remifentanil anesthesia with hemodynamic stability 
and delayed emergence [1]. Nevertheless, the 
incidence of coughing in our study was slightly 
higher than in previous studies [1, 5, 14], which may 
have resulted from the investigator’s technique 
during tracheal extubation. Furthermore, the higher 
incidence may be due to the strict application of 
cough, which we defined as even a small head 
movement with contraction of the neck muscles while 
coughing.  
Combination of dexmedetomidine and low-dose 
remifentanil infusion provided stable hemodynamics 
during emergence by attenuating cardiovascular 
response to tracheal extubation compared to high- 
dose remifentanil infusion alone, although remifen-
tanil attenuates cardiovascular change during 
emergence in a dose-dependent manner [1]. Unstable 
hemodynamics during extubation can lead to several 
serious clinical outcomes. Extreme high blood 
pressure can cause cerebral vascular events, especially 
in old patients, and rapid pulse rate can trigger 
arrhythmias. Thus, to maintain stable hemodynamics 
through smooth emergence is important. The results 
of this study can be clinically applicable in patients 
after head and neck major surgery, with un-ruptured 
cerebral aneurysm, to avoid emergence crisis - severe 
coughing, unstable hemodynamic changes.  
During infusion of dexmedetomidine, bradycar-
dia did occur, but blood pressure remained relatively 
stable, in agreement with previous studies [5, 15]. 
Rapid administration of dexmedetomidine can 
produce bradycardia or tachycardia and hypertension 
[3]. In this study we administered only 0.5 μg/kg of 
dexmedetomidine for 10 min, which is half of the dose 
recommended by the manufacturer. Thus, hemodyn-
amic changes during infusion of dexmedetomidine 
were not critical.  
We expected that addition of dexmedetomidine 
would spare patients the adverse events of high-dose 
remifentanil, such as respiratory depression or post-
operative nausea and vomiting, while simultaneously 
attenuating coughing. Dexmedetomidine in our study 
did not improve respiratory profiles, such as recovery 
of spontaneous respiration at awakening and 
respiration rate at extubation. Kim et al demonstrated 
that single dose of dexmedetomidine alone leads to 
better preservation of spontaneous respiration during 
recovery after craniotomy, compared to remifentanil 
infusion at 1.5 ng/mL of Ce [16]. This preserved 
respiration is a unique property of dexmedetomidine, 
in contrast to most sedatives, including opioids that 
depress respiration rate in a dose-dependent manner 
[14, 17]. Even addition of dexmedetomidine to 
remifentanil does not aggravate respiratory 
depression induced by remifentanil [5]. So, 
remifentanil in this combination may play a key role 
in changing respiratory profiles.  
Addition of dexmedetomidine suppressed 
postoperative nausea and vomiting in agreement with 
the previous studies. It remains unclear whether the 
antiemetic effect of dexmedetomidine might result 
from some property of its own or its opioid-sparing 
effect. The antiemetic effect of dexmedetomidine 
might lead to a small improvement in physical 
independence of QoR-40 score in the recovery profile 
at 24 h after surgery. Even, there were no significant 
statistical differences in the physical comfort, 
psychological support and pain of QoR-40 scores, the 
postoperative score of group DR in all categories 
showed smaller decrease compared with the 
preoperative score than group R. Therefore, the 
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postoperative global QoR-40 score of group DR 
showed smaller decrease than group R, when 
compared before and after surgery. This is consistent 
with previous studies showing that dexmedetomidine 
is effective in postoperative quality of recovery in 
patients [18, 19].  
Dexmedetomidine prolonged the time to 
awakening and extubation. This finding is consistent 
with the previous study that demonstrated combina-
tion of single dose of dexmedetomidine with low- 
dose remifentanil at 1.0 ng/mL of Ce delayed 
emergence compared with low-dose remifentanil 
alone [5]. Also, Chang et al showed that remifentanil 
infusion delayed emergence in a dose-dependent 
manner [7, 14]. In our study, dexmedetomidine 
combined with low-dose remifentanil at 1.0 ng/mL of 
Ce delayed emergence compared to high-dose 
remifentanil at 2.0 ng/mL of Ce. However, whether 
dexmedetomidine prolonged sedation during 
emergence remains controversial [16, 20-22]. The 
discrepancy among studies comes from the presence 
or absence of intraoperative opioids, the dose of 
dexmedetomidine, and patient characteristics. 
Therefore, clinicians should be aware that the sedative 
effect of dexmedetomidine might be associated with 
delayed awakening.  
The present study has some limitations. First, the 
sample size was calculated for a non-inferiority trial, 
which generally requires a smaller sample size than a 
superiority trial. Thus, with a sample size 159, the 
present study may be underpowered to definitively 
assess superiority of single-dose dexmedetomidine 
with respect to incidence and severity of cough or 
secondary outcome, such as respiratory profile. 
Second, postoperative nausea and vomiting and pain 
in the ward were measured indirectly through the 
number of patients using analgesics or antiemetics, 
which can bias the postoperative patient outcome 
results. Third, the anesthesiologists who assessed the 
coughing might have been able to guess the group 
assignment based on the hemodynamic changes 
during emergence. This could potentially affect the 
assessment of coughing.  
In conclusion, addition of a single dose of dexm-
edetomidine (0.5 μg/kg) to low-dose remifentanil 
infusion at 1 ng/mL of Ce during emergence from 
sevoflurane-remifentanil anesthesia was not inferior 
to a high-dose remifentanil infusion alone at 2 ng/mL 
of Ce for attenuating cough. Furthermore, a regimen 
of dexmedetomidine in addition to low-dose 
remifentanil maintained hemodynamic stability 
during emergence and reduced postoperative nausea 
and vomiting, compared to high-dose remifentanil 
alone. However, dexmedetomidine may delay 
emergence from general anesthesia. Therefore, 
addition of dexmedetomidine might be considerable 
alternative method for the smooth emergence from 
general anesthesia than the increased dose of 
remifentanil with attention to delayed awakening. 
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